Cancer Research and Treatment

Case Report

Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis: Won-Young Park, Han-Jo Kim, Kyoungha Kim, Sang-Byung Bae, Namsu Lee, Kyu-Taek Lee, Jong-Ho Won, Hee-Sook Park, Sang-Cheol Lee; Cancer Res Treat. 2016;48(2):843-847. Published online March 2, 2015; DOI: https://doi.org/10.4143/crt.2014.234

Leptomeningeal carcinomatosis is a fatal manifestation of metastatic breast cancer. Investigation of intrathecal (IT) trastuzumab for leptomeningeal carcinomatosis is currently underway; however, there has been no consensus. We report on two cases of human epidermal growth factor receptor 2 positive (HER2+) breast cancer following IT trastuzumab for leptomeningeal carcinomatosis. The first patient was treated with weekly IT 15 mg methotrexate plus IT 50 mg trastuzumab for 7 months, followed by IT trastuzumab (50 mg > 25 mg) for 18 months. The other patient received IT trastuzumab with systemic chemotherapy (trastuzumab and/or paclitaxel) for 13 months. Good control of leptomeningeal disease was achieved with IT trastuzumab in both patients, with survival durations of 20 and 29 months, respectively. We suggest that IT trastuzumab is a promising treatment for patients with HER2+ breast cancer and leptomeningeal carcinomatosis.

Citations

Citations to this article as recorded by

The research progress on meningeal metastasis in solid tumors
Yi Yue, Yuqing Ren, Chunya Lu, Nan Jiang, Sihui Wang, Junkai Fu, Mengrui Kong, Guojun Zhang
Discover Oncology.2025;[Epub] CrossRef
An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?
Mainak Bardhan, Debankur Dey, Vinay Suresh, Binish Javed, Vyshak Alva Venur, Neha Joe, Ritvika Kalidindi, Ahmad Ozair, Marium Khan, Reshma Mahtani, Simon Lo, Yazmin Odia, Manmeet S. Ahluwalia
Expert Review of Neurotherapeutics.2024; 24(1): 77. CrossRef
Intrathecal Trastuzumab for HER2-Positive Cancer of Unknown Primary Leptomeningeal Metastasis: A Case Report
Kohei Oka, Shun Futamura, Taishi Harada
Cureus.2024;[Epub] CrossRef
A Review on the Efficacy and Safety of Intrathecal Administration of Novel Medications for Leptomeningeal Metastases in Solid Cancers
Fatemeh Jafari, Mohammad Moeini Nodeh, Hesamoddin Hosseinjani, Hamed Baharara, Sajad Azad, Omid Arasteh, Thomas P. Johnston, Amirhossein Sahebkar
Current Medicinal Chemistry.2024; 31(19): 2732. CrossRef
Leptomeningeal Carcinomatosis from Solid Tumor Malignancies: Treatment Strategies and Biomarkers
Rachna Malani, Ankush Bhatia, Allison Betof Warner, Jonathan T. Yang
Seminars in Neurology.2023; 43(06): 859. CrossRef
Leptomeningeal metastases: the future is now
Rimas V. Lukas, Jigisha P. Thakkar, Massimo Cristofanilli, Sunandana Chandra, Jeffrey A. Sosman, Jyoti D. Patel, Priya Kumthekar, Roger Stupp, Maciej S. Lesniak
Journal of Neuro-Oncology.2022; 156(3): 443. CrossRef
Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review
Yajing Chi, Mao Shang, Liang Xu, Heyi Gong, Rongjie Tao, Lihua Song, Baoxuan Zhang, Sha Yin, Binbin Cong, Huihui Li
Frontiers in Oncology.2022;[Epub] CrossRef
Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression
Flora Zagouri, Panagiotis Zoumpourlis, Emilie Le Rhun, Rupert Bartsch, Eleni Zografos, Kleoniki Apostolidou, Meletios-Athanasios Dimopoulos, Matthias Preusser
Cancer Treatment Reviews.2020; 88: 102046. CrossRef
Leptomeningeal carcinomatosis in patients with breast cancer
Maria Alice Franzoi, Gabriel N. Hortobagyi
Critical Reviews in Oncology/Hematology.2019; 135: 85. CrossRef
Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy
Nicholas B. Figura, Victoria T. Rizk, Homan Mohammadi, Brittany Evernden, Sepideh Mokhtari, H. Michael Yu, Timothy J. Robinson, Arnold B. Etame, Nam D. Tran, James Liu, Iman Washington, Roberto Diaz, Brian J. Czerniecki, Hatem Soliman, Hyo S. Han, Solmaz
Breast Cancer Research and Treatment.2019; 175(3): 781. CrossRef
Breast leptomeningeal disease: a review of current practices and updates on management
Nicholas B. Figura, Victoria T. Rizk, Avan J. Armaghani, John A. Arrington, Arnold B. Etame, Hyo S. Han, Brian J. Czerniecki, Peter A. Forsyth, Kamran A. Ahmed
Breast Cancer Research and Treatment.2019; 177(2): 277. CrossRef
Medical Management of Brain Metastases and Leptomeningeal Disease in Patients with Breast Carcinoma
Kelsey M Bowman, Priya Kumthekar
Future Oncology.2018; 14(4): 391. CrossRef
Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience
Nicholas B. Figura, Wendy Long, Michael Yu, Timothy J. Robinson, Sepideh Mokhtari, Arnold B. Etame, Nam D. Tran, Roberto Diaz, Hatem Soliman, Heather S. Han, Solmaz Sahebjam, Peter A. Forsyth, Kamran A. Ahmed
Breast Cancer Research and Treatment.2018; 169(2): 391. CrossRef
Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches
Niyanta N. Kumar, Michelle E. Pizzo, Geetika Nehra, Brynna Wilken-Resman, Sam Boroumand, Robert G. Thorne
Bioconjugate Chemistry.2018; 29(12): 3937. CrossRef
Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era
J. Remon, E. Le Rhun, B. Besse
Cancer Treatment Reviews.2017; 53: 128. CrossRef
Current challenges in the management of breast cancer brain metastases
Ciara C. O’Sullivan, Nicole N. Davarpanah, Jame Abraham, Susan E. Bates
Seminars in Oncology.2017; 44(2): 85. CrossRef
Leptomeningeal disease: current diagnostic and therapeutic strategies
Gautam Nayar, Tiffany Ejikeme, Pakawat Chongsathidkiet, Aladine A. Elsamadicy, Kimberly L. Blackwell, Jeffrey M. Clarke, Shivanand P. Lad, Peter E. Fecci
Oncotarget.2017; 8(42): 73312. CrossRef
Leptomeningeal metastases of solid cancer
Emilie Le Rhun, Evanthia Galanis
Current Opinion in Neurology.2016; 29(6): 797. CrossRef
Metastatic breast cancer: The Odyssey of personalization
A. Sonnenblick, N. Pondé, M. Piccart
Molecular Oncology.2016; 10(8): 1147. CrossRef
Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?
Eleonora Teplinsky, Francisco J. Esteva
Current Oncology Reports.2015;[Epub] CrossRef

16,585 View
193 Download
21 Web of Science
20 Crossref

Original Article

A Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin for Treatment in Patients with Previously Untreated Advanced Colorectal Cancer: Sang-Byung Bae, Nam-Su Lee, Han-Jo Kim, Kyoung-Ha Kim, Hyun-Jung Kim, Chan-Kyu Kim, Kyu-Taeg Lee, Sung-Kyu Park, Jong-Ho Won, Dae-Sik Hong, Hee-Sook Park; Cancer Res Treat. 2006;38(2):72-77. Published online April 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.2.72

Abstract PDF PubReader ePub

Purpose

We prospectively conducted a non-randomized phase II trial to evaluate the efficacy and safety of combination irinotecan, leucovorin (LV) and 5-fluorouracil (FU) as a first-line regimen for treating patients with previously untreated advanced colorectal cancer (CRC).

Materials and Methods

Twenty-six previously untreated patients with advanced, recurrent or metastatic CRC were enrolled in this study. The patients received either irinotecan 180 mg/m² on day 1 with LV bolus of 200 mg/m² and FU bolus of 400 mg/m², and this was followed by FU continuous infusion of 600 mg/m² on day 1 and day 2 (the FOLFIRI regimen), or they were treated with LV bolus of 400 mg/m² and FU bolus of 400 mg/m² followed by FU continuous infusion of 2,400 mg/m² for 46 hours (the simplified FOLFIRI regimen), and these treatments were repeated every 2 weeks until disease progression.

Results

The objective response rate was 23.1% (6/26) respectively, for both treatments. The median time to progression was 5.3 months (range: 0.4~19.9), and the overall survival was 11.2 months (range: 0.5~52.3). The prognostic factor for longer survival was the Eastern Cooperative Oncology Group (ECOG) performance status (PS). The non-hematological toxicities were similar for both treatment groups, with more frequent grade ≥3 neutropenia being noted for the simplified FOLFIRI regimen.

Conclusion

The biweekly irinotecan based regimen was demonstrated to have a moderate antitumor activity with acceptable toxicity profiles, and the ECOG PS was the independent prognostic factor.

Citations

Citations to this article as recorded by

Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review
Louise André, Gabriel Antherieu, Amélie Boinet, Judith Bret, Thomas Gilbert, Rabia Boulahssass, Claire Falandry
Cancers.2022; 14(10): 2470. CrossRef
The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab
B. Budai, T. Nagy, I. Láng, E. Hitre
Angiogenesis.2013; 16(1): 113. CrossRef
Successful Treatment of Small-Cell Lung Cancer With Irinotecan in a Hemodialysis Patient With End-Stage Renal Disease
Dong Min Kim, Hyun Lee Kim, Choon Hae Chung, Chi Young Park
The Korean journal of internal medicine.2009; 24(1): 73. CrossRef

12,100 View
68 Download
3 Crossref

First
Prev
Page of 1
Next
Last

Search